Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

Christopher A. Eide; Stephen E. Kurtz; Andy Kaempf; Nicola Long; Anupriya Agarwal; Cristina E. Tognon; Motomi Mori; Brian J. Druker; Bill H. Chang; Alexey V. Danilov; Jeffrey W. Tyner

doi:10.1038/s41375-020-0764-6

Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Anupriya Agarwal, Cristina E. Tognon, Motomi Mori, Brian J. Druker, Bill H. Chang, Alexey V. Danilov, Jeffrey W. Tyner

Research output: Contribution to journal › Article

Abstract

Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR + VEN), currently in clinical trials for chronic lymphocytic leukemia (CLL), demonstrated enhanced efficacy on primary AML patient specimens, AML cell lines, and in a mouse xenograft model of AML. Expanded analyses among a large cohort of hematologic malignancies (n = 651 patients) revealed that IBR + VEN sensitivity associated with selected genetic and phenotypic features in both CLL and AML specimens. Among AML samples, 11q23 MLL rearrangements were highly sensitive to IBR + VEN. Analysis of differentially expressed genes with respect to IBR + VEN sensitivity indicated pathways preferentially enriched in patient samples with reduced ex vivo sensitivity, including IL-10 signaling. These findings suggest that IBR + VEN may represent an effective therapeutic option for patients with AML.

Original language	English (US)
Journal	Leukemia
DOIs	https://doi.org/10.1038/s41375-020-0764-6
State	Accepted/In press - Jan 1 2020

Fingerprint

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Cite this

Eide, C. A., Kurtz, S. E., Kaempf, A., Long, N., Agarwal, A., Tognon, C. E., Mori, M., Druker, B. J., Chang, B. H., Danilov, A. V., & Tyner, J. W. (Accepted/In press). Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. https://doi.org/10.1038/s41375-020-0764-6

Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. / Eide, Christopher A.; Kurtz, Stephen E.; Kaempf, Andy; Long, Nicola; Agarwal, Anupriya; Tognon, Cristina E.; Mori, Motomi ; Druker, Brian J.; Chang, Bill H.; Danilov, Alexey V.; Tyner, Jeffrey W.

In: Leukemia, 01.01.2020.

Research output: Contribution to journal › Article

Eide, Christopher A. ; Kurtz, Stephen E. ; Kaempf, Andy ; Long, Nicola ; Agarwal, Anupriya ; Tognon, Cristina E. ; Mori, Motomi ; Druker, Brian J. ; Chang, Bill H. ; Danilov, Alexey V. ; Tyner, Jeffrey W. / Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. In: Leukemia. 2020.

@article{279e7f03609f43729bf1453d348d6026,

title = "Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia",

abstract = "Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR + VEN), currently in clinical trials for chronic lymphocytic leukemia (CLL), demonstrated enhanced efficacy on primary AML patient specimens, AML cell lines, and in a mouse xenograft model of AML. Expanded analyses among a large cohort of hematologic malignancies (n = 651 patients) revealed that IBR + VEN sensitivity associated with selected genetic and phenotypic features in both CLL and AML specimens. Among AML samples, 11q23 MLL rearrangements were highly sensitive to IBR + VEN. Analysis of differentially expressed genes with respect to IBR + VEN sensitivity indicated pathways preferentially enriched in patient samples with reduced ex vivo sensitivity, including IL-10 signaling. These findings suggest that IBR + VEN may represent an effective therapeutic option for patients with AML.",

author = "Eide, {Christopher A.} and Kurtz, {Stephen E.} and Andy Kaempf and Nicola Long and Anupriya Agarwal and Tognon, {Cristina E.} and Motomi Mori and Druker, {Brian J.} and Chang, {Bill H.} and Danilov, {Alexey V.} and Tyner, {Jeffrey W.}",

year = "2020",

month = jan,

day = "1",

doi = "10.1038/s41375-020-0764-6",

language = "English (US)",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

AU - Eide, Christopher A.

AU - Kurtz, Stephen E.

AU - Kaempf, Andy

AU - Long, Nicola

AU - Agarwal, Anupriya

AU - Tognon, Cristina E.

AU - Mori, Motomi

AU - Druker, Brian J.

AU - Chang, Bill H.

AU - Danilov, Alexey V.

AU - Tyner, Jeffrey W.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR + VEN), currently in clinical trials for chronic lymphocytic leukemia (CLL), demonstrated enhanced efficacy on primary AML patient specimens, AML cell lines, and in a mouse xenograft model of AML. Expanded analyses among a large cohort of hematologic malignancies (n = 651 patients) revealed that IBR + VEN sensitivity associated with selected genetic and phenotypic features in both CLL and AML specimens. Among AML samples, 11q23 MLL rearrangements were highly sensitive to IBR + VEN. Analysis of differentially expressed genes with respect to IBR + VEN sensitivity indicated pathways preferentially enriched in patient samples with reduced ex vivo sensitivity, including IL-10 signaling. These findings suggest that IBR + VEN may represent an effective therapeutic option for patients with AML.

AB - Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR + VEN), currently in clinical trials for chronic lymphocytic leukemia (CLL), demonstrated enhanced efficacy on primary AML patient specimens, AML cell lines, and in a mouse xenograft model of AML. Expanded analyses among a large cohort of hematologic malignancies (n = 651 patients) revealed that IBR + VEN sensitivity associated with selected genetic and phenotypic features in both CLL and AML specimens. Among AML samples, 11q23 MLL rearrangements were highly sensitive to IBR + VEN. Analysis of differentially expressed genes with respect to IBR + VEN sensitivity indicated pathways preferentially enriched in patient samples with reduced ex vivo sensitivity, including IL-10 signaling. These findings suggest that IBR + VEN may represent an effective therapeutic option for patients with AML.

UR - http://www.scopus.com/inward/record.url?scp=85079788016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079788016&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0764-6

DO - 10.1038/s41375-020-0764-6

M3 - Article

AN - SCOPUS:85079788016

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -

Access to Document

10.1038/s41375-020-0764-6